GTx has declared results of a Phase II clinical trial evaluating Ostarine, an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known
For the quarter, the Company announced adjusted earnings per share of $0.03, compared with $0.08 in the corresponding period a year ago. Quarterly Highlights — Net revenue of
Medivation has completed patient enrollment in the six-month, confirmatory, pivotal Phase-III trial of the investigational drug dimebon, in patients with mild-to-moderate Alzheimer’s disease. The pivotal Phase-III study enrolled
California-based Orexigen has announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK), that expands the company’s IP position underlying Contrave, its lead product candidate for the
Regeneron has signed two royalty agreements with Novartis that replaces previous collaboration and license agreement. Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide
Neuromed has received notification that Merck will terminate the research collaboration and license agreement for novel compounds targeting N-type calcium channels, for the treatment of pain and other
Jubilant Organosys has announced that its Bangalore-based subsidiary, Jubilant Biosys has entered into a discovery and development collaboration with Endo Pharmaceuticals. Under the terms of the agreement, Jubilant
Human Genome Sciences has announced the positive long-term Phase-II trial data for Benlysta (belimumab, formerly LymphoStat-B) in patients with active systemic lupus erythematosus. Benlysta is a human monoclonal
Xenon has announced a strategic alliance with Merck through an affiliate, to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease. In collaboration
Watson has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its guaifenesin pseudoephedrine HCI extended-release 600mg/60mg and 1200mg/120mg tablets prior to the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.